Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06019338 · ClinicalTrials.gov registry record
A Study to Validate a Pain Diary for Patient With Trigeminal Neuralgia
A clinical trial, sponsored by Noema Pharma.
- Completed
- Registry status
- 30
- Enrollment target
NCT06019338: Completed study, sponsored by Noema Pharma.
NCT06019338 is a clinical trial that has completed, run by Noema Pharma. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06019338 has completed, sponsored by Noema Pharma.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
The aim of the study is to establish the validity of a patient reported diary in TN . The following objectives have been identified: 1. To generate evidence to support diary content validity by performing qualitative research studies with TN patients and Healthcare Professionals (HCPs). 2. To provide further support to the diary, sensitivity to change, known groups validity (ability to differentiate between severity groups), and construct validity.
Primary Outcome
Use of the TN Pain questionnaire to measure the pain associated with trigeminal neuralgia
Interventions
- OTHER Pain Diary use
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-11-20 |
| Est. Completion | 2023-08-31 |
What the finished NCT06019338 record still lists
NCT06019338 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pain Diary use is the first listed.
NCT06019338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06019338 about?
NCT06019338 is a clinical study titled "A Study to Validate a Pain Diary for Patient With Trigeminal Neuralgia". The aim of the study is to establish the validity of a patient reported diary in TN . The following objectives have been identified: 1. To generate evidence to support diary content validity by performing qualitative research studies with TN patients and Healthcare Professionals (HCPs). 2. To provi...
What is the current status of trial NCT06019338?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2021-11-20. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT06019338?
The interventions under investigation include: Pain Diary use (OTHER).
Who is sponsoring clinical trial NCT06019338?
This trial is sponsored by Noema Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI